Log in using OpenID

PharmaPoint, Melanoma - Global Drug Forecast and Market Analysis to 2023

Big Market Research present “PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.c
PharmaPoint: Melanoma
Global Drug Forecast and Market Analysis to 2023
Report Description:
Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for
melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies.
GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the
8MM covered in this report. The market will increase by four-fold over the forecast period,
reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in
melanoma incident cases as well as the approval and uptake of premium-priced products, such
as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end
of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma
market (including both BRAF wild-type and mutation-positive patient segments) with an
overall 67% share of the melanoma market.
The melanoma pipeline is strong; however, GlobalData expects none of these drugs to have a
major impact on the overall melanoma market, as the market is crowded with effective
immunotherapies and BRAF mutation-targeted agents.
Read more details at :
Report Description:
Key Questions Answered
- The melanoma space is filled with the excitement of recently approved anti-PD-1
immunotherapies, which are expected to revolutionize the treatment landscape. What will
be the impact of these newly approved drugs and their projected label expansions on the
melanoma sales?
- As the melanoma market is getting increasingly crowded with multiple anti-PD-1
immunotherapies and BRAF mutation-targeted agents, opportunities for new entrants
become limited. What R&D strategies are being used by drug makers to remain
- The survival of patients with metastatic melanoma remains short, especially for those
who do not response to anti-PD-1 immunotherapies. Therefore, there are considerably high
unmet needs within the indication. What are the main unmet needs in this market. Will the
drugs under development fulfil the unmet needs of the melanoma market?
Key Findings
Key Findings
- One of the main drivers of the enormous expansion of the gout market will be the launch of
premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK
inhibitor combinations. These drugs will extend treatment duration and replace cheaper,
generic, chemotherapy regimens.
- Another strong driver will be the label extension of current therapies into the new settings;
for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and
the metastatic brands are expected to be approved in the adjuvant setting in the second
half of the forecast period.
- Companies are focusing on the development of combination immunotherapies, trying to
improve the response rate and response duration of drugs.
- One of the largest unmet needs is a need for efficacious treatment options for BRAF wildtype patients. Approximately half of melanoma patients do not have BRAF mutations, and
are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include
therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with
resected melanoma, effective treatment for brain metastasis
- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and disease management.
- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and
treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and
BRAF wild-type), forecast from 2013 to 2023.
- Key topics covered include strategic competitor assessment, market characterization,
unmet needs, clinical trial mapping and implications for the melanoma therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action
under development for different lines of therapy. The most promising candidate in Phase III
development is profiled.
Reasons to buy:
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies with the most robust
- Develop business strategies by understanding the trends shaping and driving the global
melanoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments, and companies likely to impact the global melanoma therapeutics market
in the future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analysing the performance of various competitors.
- About Report:
Visit us at :
Stay With Us:
TELEPHONE: + 1-800-910-6452
[email protected]
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Report inappropriate content